Botulinum toxin type a
Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| digestive system diseases | D004066 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| skin and connective tissue diseases | D017437 |
| signs and symptoms pathological conditions | D013568 |
| integumentary system physiological phenomena | D055827 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| daxxify | Biologic Licensing Application | 2023-03-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| blepharospasm | — | D001764 | G24.5 |
| dystonia | HP_0001332 | D004421 | G24 |
| fissure in ano | HP_0012390 | D005401 | K60.2 |
| genetic skin diseases | — | D012873 | — |
| muscle rigidity | HP_0002063 | D009127 | — |
| strabismus | HP_0000486 | D013285 | H50.2 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
887 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 5 | 11 | 18 | 16 | 16 | 63 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 4 | 9 | 16 | 14 | 7 | 47 |
| Cerebral palsy | D002547 | G80 | 2 | 8 | 15 | 4 | 14 | 40 | |
| Torticollis | D014103 | HP_0000473 | F45.8 | 5 | 8 | 11 | 7 | 8 | 37 |
| Muscle spasticity | D009128 | HP_0001257 | 1 | 5 | 11 | 8 | 11 | 36 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 5 | 9 | 7 | 6 | 27 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 4 | 10 | 5 | 5 | 24 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | 3 | 2 | 5 | 4 | 3 | 15 |
| Hyperhidrosis | D006945 | HP_0000975 | 3 | 2 | 2 | 4 | 4 | 15 | |
| Blepharospasm | D001764 | G24.5 | 1 | 3 | 5 | 4 | 2 | 13 |
Show 78 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | 5 | — | 3 | 8 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | 4 | 2 | — | 2 | 7 |
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 3 | — | 1 | 6 |
| Temporomandibular joint disorders | D013705 | M26.6 | 1 | 2 | 2 | — | 1 | 5 | |
| Vulvodynia | D056650 | N94.81 | — | 1 | 3 | — | — | 4 | |
| Headache | D006261 | HP_0002315 | R51 | — | — | 2 | — | 2 | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | 1 | — | — | 3 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | 3 | 2 | — | — | 3 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | 2 | 2 | 1 | — | — | 3 |
| Paresis | D010291 | HP_0001269 | — | 2 | 1 | — | — | 3 |
Show 26 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 3 | — | — | — | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 2 | 3 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | 1 | 1 | — | — | 1 | 3 | |
| Neck pain | D019547 | HP_0030833 | M54.2 | 2 | 1 | — | — | 1 | 3 |
| Smiling | D012904 | — | 1 | — | — | 1 | 2 | ||
| Abdominal hernia | D046449 | K46 | — | 1 | — | — | 1 | 2 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 2 | — | — | — | 2 |
| Traumatic brain injuries | D000070642 | S06 | — | 2 | — | — | — | 2 | |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | 1 | 2 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
| Hemorrhagic stroke | D000083302 | 1 | — | — | — | — | 1 | ||
| Internal carotid artery dissection | D020215 | 1 | — | — | — | — | 1 | ||
| Vertebral artery dissection | D020217 | I77.74 | 1 | — | — | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Gingival overgrowth | D019214 | K06.1 | 1 | — | — | — | — | 1 | |
| Treatment-resistant depressive disorder | D061218 | 1 | — | — | — | — | 1 | ||
| Complex regional pain syndromes | D020918 | EFO_1001998 | 1 | — | — | — | — | 1 | |
| Secondary headache disorders | D051271 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystonia | D004421 | HP_0001332 | G24 | — | — | — | — | 2 | 2 |
| Diffuse esophageal spasm | D015155 | EFO_1001785 | K22.4 | — | — | — | — | 2 | 2 |
| Strabismus | D013285 | HP_0000486 | H50.2 | — | — | — | — | 2 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 2 | 2 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
| Hidradenitis suppurativa | D017497 | L73.2 | — | — | — | — | 2 | 2 | |
| Activities of daily living | D000203 | — | — | — | — | 1 | 1 | ||
| Botulism | D001906 | EFO_0005542 | A05.1 | — | — | — | — | 1 | 1 |
| Pancreatic fistula | D010185 | — | — | — | — | 1 | 1 | ||
| Treatment outcome | D016896 | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BOTULINUM TOXIN TYPE A |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin (BoNT), is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It is also known as Botulin, the density of which is predicted to be 1.5±0.1 g/cm3.
It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
|
| Classification | Neurotoxin |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297862 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,652 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,252 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more